Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets Fed Study

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ranbaxy Inc. ( Ranbaxy Laboratories Limited )
ClinicalTrials.gov Identifier:
NCT01654718
First received: June 21, 2012
Last updated: July 28, 2012
Last verified: June 2012

June 21, 2012
July 28, 2012
October 2008
November 2008   (final data collection date for primary outcome measure)
Composite of Pharmacokinetics [ Time Frame: Predose and at 1.00, 2.00, 3.00, 3.50, 4.00, 4.50, 5.00, 5.50, 6.00, 6.50, 7.00, 7.50, 8.00, 8.50, 9.00, 9.50, 10.00, 10.50, 11.00, 12.00, 13.00, 14.00, 15.00, 16.00, 17.00, 18.00, 19.00, 20.00, 22.00, 24.00, 36.00 and 48.00 hours ] [ Designated as safety issue: No ]
Cmax, Area Under Curve and Tmax
Same as current
Complete list of historical versions of study NCT01654718 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets Fed Study
An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover Bioequivalence Study Comparing Pantoprazole Sodium 40 mg Delayed Release Tablets (Containing 45.1 mg of Pantoprazole Sodium Sesquihydrate is Equivalent to 40 mg of Pantoprazole) of OHM Laboratories Inc. USA (a Subsidiary of Ranbaxy Pharmaceuticals Inc. USA) With PROTONIX® 40 mg Delayed Release Tablets (Containing 45.1 mg of Pantoprazole Sodium Sesquihydrate is Equivalent to 40 mg of Pantoprazole) of Wyeth Laboratories in Healthy, Adult, Human, Male Subjects Under Fed Conditions.

This study was to compare the single-dose oral bioequivalence of Pantoprazole sodium 40 mg delayed release tablets (containing 45.1 mg of Pantoprazole sodium sesquihydrate is equivalent to 40 mg of Pantoprazole) of OHM Laboratories Inc. USA (a subsidiary of Ranbaxy Pharmaceuticals Inc. USA) with PROTONIX® 40 mg delayed release tablets (containing 45.1 mg of Pantoprazole sodium sesquihydrate is equivalent to 40 mg of Pantoprazole) of Wyeth Laboratories, USA in healthy, adult, human, male subjects under fed conditions.

The study was an open-label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence under fed conditions

A washout period of 08 days was enforced between the administrations of study drugs in each period. At study check-in, the subjects reported to the clinical site at least 36 hours prior to Day 1 dosing and were required to stay for 24 hours after Day 1 dosing. Blood sample collections were obtained within 90 minutes prior to dosing (0 hour) and after dose administration at periodic interval up to 48.00 hour in each period. A total number of blood draws during the study were sixty six (66) and the total volume of blood drawn did not exceed 324 mL.

Following an overnight fast of at least 10 hour, a high-fat high-calorie breakfast was served to the study subjects. Thirty minutes after start of this breakfast, a single oral dose of Pantoprazole delayed release tablet 40 mg of either test or reference formulation was administered during each period of the study, along with 240 mL of drinking water at ambient temperature under low light condition and under supervision of trained study personnel. Both test and reference products were administered to all the study subjects, one in each period.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Healthy
  • Drug: Pantoprazole
    Pantoprazole 40mg Delayed release tablets (Test Product)
  • Drug: Pantoprazole
    Protonix® Delayed Release 40 mg tablets (Reference product)
  • Experimental: Pantoprazole Sodium Delayed release tablets
    Pantoprazole Sodium Delayed release tablets USP 40 mg of OHM Laboratories Inc.,USA
    Intervention: Drug: Pantoprazole
  • Active Comparator: Protonix® Delayed Release 40 mg tablets
    Protonix® Delayed Release 40 mg tablets of Wyeth Pharmaceuticals Inc.USA
    Intervention: Drug: Pantoprazole
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
November 2009
November 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

Volunteers who met the following criteria were included in the study

  • Were in the age range of 18-45 years.
  • Were neither overweight nor underweight for his height as per the Life Insurance Corporation of India height/weight chart for non-medical cases.
  • Had voluntarily given written informed consent to participate in this study.
  • Were of normal health as determined by medical history and physical examination of the subjects performed within 21 days prior to the commencement of the study.
  • Had non-vegetarian dietary habit.

There were no deviations in this regard

Exclusion Criteria:

  • History of allergy or hypersensitivity to Pantoprazole and/or any other drugs.
  • Any evidence of organ dysfunction or any clinically significant deviation from the normal, in physical or clinical determinations.
  • Presence of disease markers of HIV 1 or 2, Hepatitis B or C viruses or syphilis infection.
  • Presence of values which were out of acceptable limits for haemoglobin, total white blood cells count, differential WBC count or platelet count.
  • Positive for urinary screen testing of drugs of abuse (opiates or cannabinoids).
  • Presence of values which were out of acceptable limits for serum creatinine, blood urea nitrogen, serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), serum alkaline phosphatase, serum bilirubin, plasma glucose or serum cholesterol.
  • Clinically abnormal chemical and microscopic examination of urine defined as presence of RBC, WBC (>4/HPF), epithelial cells (>4/HPF), glucose (positive) or protein (positive).
  • Clinically abnormal ECG or Chest X-ray.
  • History of serious gastrointestinal, hepatic, renal, cardiovascular, pulmonary, neurological or haematological disease, diabetes or glaucoma.
  • History of any psychiatric illness which might impair the ability to provide written informed consent.
  • Regular smokers who smoked more than 10 cigarettes daily or had difficulty abstaining from smoking for the duration of each study period.
  • History of drug dependence or excessive alcohol intake on a habitual basis of more than 2 units of alcoholic beverages per day (1 unit equivalent to half pint of beer or 1 glass of wine or 1 measure of spirit) or had difficulty in abstaining for the duration of each study period.
  • Use of any enzyme modifying drugs within 30 days prior to Day 1 of this study.
  • Participation in any clinical trial within 12 weeks preceding Day 1 of this study.
  • Subjects who, through completion of this study, would have donated and /or lost more than 350 ml of blood in the past 3 months other than study participation.

There were no deviations in this regard.

Male
20 Years to 37 Years
Yes
Contact information is only displayed when the study is recruiting subjects
India
 
NCT01654718
251_PANTO_08
No
Ranbaxy Inc. ( Ranbaxy Laboratories Limited )
Ranbaxy Laboratories Limited
Not Provided
Not Provided
Ranbaxy Inc.
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP